These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 28756084)
41. The emerging role of carfilzomib combination therapy in the management of multiple myeloma. Moreau P Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249 [TBL] [Abstract][Full Text] [Related]
42. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Stewart AK Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319 [TBL] [Abstract][Full Text] [Related]
43. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Dimopoulos MA; San-Miguel JF; Anderson KC Eur J Haematol; 2011 Jan; 86(1):1-15. PubMed ID: 20942854 [TBL] [Abstract][Full Text] [Related]
44. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103 [TBL] [Abstract][Full Text] [Related]
45. The challenge of cross-trial comparisons using limited data. Laubach JP; Faber EA; Voorhees P; Moslehi J; Varga C; Niculescu L; Anderson KC; Richardson PG Haematologica; 2014 Aug; 99(8):e145-6. PubMed ID: 25082787 [No Abstract] [Full Text] [Related]
46. Recent trends in the management of newly diagnosed multiple myeloma. Reece DE Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669 [TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics of patients with relapsed multiple myeloma. Dimopoulos MA; Terpos E; Niesvizky R; Palumbo A Cancer Treat Rev; 2015 Dec; 41(10):827-35. PubMed ID: 26296679 [TBL] [Abstract][Full Text] [Related]
48. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Nooka AK Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231 [TBL] [Abstract][Full Text] [Related]
56. New drugs in multiple myeloma. Berenson JR; Yellin O Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422 [TBL] [Abstract][Full Text] [Related]
57. Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. Suzuki T; Maruyama D; Iida S; Nagai H Jpn J Clin Oncol; 2022 Sep; 52(9):966-974. PubMed ID: 35830865 [TBL] [Abstract][Full Text] [Related]
58. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma. Spencer A; Walker P; Asvadi P; Campbell DH; Reed K; Herbert BR; Breen EJ; Copeman MC; Dunn RD Blood Cancer J; 2019 Jul; 9(8):58. PubMed ID: 31366914 [No Abstract] [Full Text] [Related]
59. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors. Yalnız FF; Akkoç N; Salihoğlu A; Ar MC; Öngören Ş; Eşkazan AE; Soysal T; Aydın Y Turk J Haematol; 2017 Aug; 34(3):233-238. PubMed ID: 28270368 [TBL] [Abstract][Full Text] [Related]
60. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]